NMES1 is a gene of unknown function first characterized in 2002. Reduction of the expression of this gene has been implicated in skin tumorigenesis in mice. Expression of NMES1 is observed in epithelial tissue but expression in the testis is significantly higher than in epidermis. Because stallion fertility is an economically important trait, we decided to characterize the NMES1 gene in stallions. We screened the CHORI241 library and obtained the full length equine NMES1 genomic sequence by direct sequencing off of clone CH241-11J8. In order to experimentally determine the 5’ and 3’ untranslated regions (UTRs) we conducted RLM-RACE experiments using stallion testis RNA. The equine NMES1 mRNA is 534 nt long and contains 5 exons. Fluorescence in situ hybridization mapped NMES1 to chromosome Eca1q23. In situ experiments to testis tissue sections were inconclusive and yielded no data confirming the physical expression pattern of NMES1 in stallion testis tissue. In order to determine the expression pattern of NMES1 mRNA we conducted qRT-PCR assays on a panel of stallion testis samples from horses with normal and abnormal fertility. We found that expression was variable among both groups, with significantly less expression in some individuals. We also conducted the qRT-PCR assay on a panel of five equine tissues and found that the expression of NMES1 was more than 100-fold greater in testis than in other tissues examined. miR-147b is a miRNA of unknown target found within the 3’ UTR of NMES1. We conducted a miRNA qRT-PCR assay to determine the expression levels in stallion testis samples from fertile and sub-fertile stallions. We observed similar expression among both groups and the ratio of mRNA to miRNA did not appear constant. We also investigated miR-147b expression in a panel of five equine tissues and found that equine spleen had more than 8-fold greater expression than testis.

Prostate cancer is the second most common cancer in the United States that affects men today. To better treat this disease accurate biomarkers and successful therapeutic treatments are needed. A novel approach to understand the mechanisms behind prostate cancer tumor formation lies in identifying dysregulated micro-RNAs (miRNAs), which are a class of small (18-24 nucleotides) non-coding RNAs that regulate gene expression posttranscriptionally by either inhibiting protein synthesis or signaling messenger-RNA for degradation. Multiple miRNAs were discovered in our highly tumorigenic and metastatic prostate cancer progression model M12 cell line compared to its weakly tumorigenic P69 parental cell line. Various analyses such as human panel analyses, single-miR analyses and patient tumor biopsy samples were analyzed to determine dysregulated miRNAs that contributed to the progression and metastasis of prostate cancer. Together with performing experiments to identify miRNAs, a de novo next generation sequencing approach was applied to identify miRNAs naturally present in biological fluids of normal and healthy subjects. Since, these miRNAs are highly dysregulated in many diseases, including cancer, they can act as potential biomarkers or therapeutic targets to improve treatments for prostate cancer. Essential miRNAs studied for this research were miR-17-3p that is known to target the ErbB2 mRNA; miR-299-5p that directly targets osteopontin (OPN) mRNA, and miR-147b that directly targets many mRNAs, such as COL4A2, ALDH5A1, NDUFA4, SDHD, and IER5. A wide range of miRNAs were identified in six biological fluids: venous blood, menstrual blood, vaginal fluid, semen, saliva, and feces. There were some miRNAs that were common to all 6 body fluids, some unique to each body fluid, and some miRNAs that literature suggested could potentially be biomarkers or normalizers for body fluid characterization.